Facility will position the firm as a large-scale producer of highly potent APIs.
Lonza reports that it is expanding its production capacities for highly potent APIs. The new manufacturing site will be built in Visp, Switzerland.
Lonza will invest more than CHF 80 million, or about $64.38 million, and expects to hire approximately 40 new employees until 2009 due to this investment.
“We are excited about being able to offer our customers a unique facility for the large-scale production of highly potent APIs,” notes Uwe Böhlke,head of Lonza Exclusive Synthesis (LES). “Additionally, this new facility supports the overall LES growth strategy as it provides Lonza with new commercial-scale production capacity in the face of high capacity utilization at Lonza’s existing cGMP small molecule facilities at Visp and Conshohocken, PA.”